- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02587819
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
An Open-Label Phase 1 Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment When Applied Twice Daily for 28 Days in Male and Female Patients With Basal Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female adults ≥ 18 years of age;
- One primary histologically confirmed BCC lesion, not located on the hand or foot, suitable for surgical excision, with a minimum area of 0.5 cm2 and a maximum diameter of 2.0 cm (histological diagnosis made no more than 4 weeks prior to the Screening visit.
- Willing to refrain from using non-approved lotions or creams on the BCC treatment site and surrounding area during the treatment period and from washing the treated area for at least 8 hours following each application of study medication;
- Ability to follow study instructions and likely to complete all study requirements;
- Written informed consent obtained, including consent for biopsy tissue to be examined and stored by the central dermatopathologist;
- Written consent to allow photographs of the BCC lesion to be used as part of the study data;
- For females of childbearing potential, a negative pregnancy test at Screening and use of an acceptable form of birth control.
Exclusion Criteria:
- Pregnant, lactating, or planning pregnancy during the study;
- Presence of known or suspected systemic cancer;
- Histological evidence of squamous cell carcinoma (SCC) or any tumor other than BCC in the biopsy specimen;
- Histological evidence of severe squamous metaplasia, infiltrative, desmoplastic, or micronodular growth patterns in the biopsy specimen;
- Evidence of dermatological disease or confounding skin condition within the 25-cm2 treatment area, eg, SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, or xeroderma pigmentosa;
- Concurrent disease or treatment that suppresses the immune system;
- Chronic medical condition that in the judgment of the investigator would interfere with the performance of the study or would place the patient at undue risk;
- Known sensitivity to any of the ingredients in the study medication;
- Treatment with systemic chemotherapeutic agents (eg, methotrexate, paclitaxel) within the 6 months prior to the Baseline visit;
- Use of systemic retinoids within the 6 months prior to the Baseline visit;
- Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the Baseline visit;
- Use of topical immunomodulators within 2 cm of the target treatment area within the 4 weeks prior to the Baseline visit;
- Treatment with topical agents for the treatment of BCC or actinic keratosis within 2 cm of the target treatment area within the 4 weeks prior to the Baseline visit:
- Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target treatment area during the 4 weeks prior to the Baseline visit;
- Clinically significant abnormalities as noted in the screening ECG, physical examination, or laboratory test results;
- Evidence of current chronic alcohol or drug abuse which, in the investigator's opinion, might interfere with the subject's adherence to protocol requirements;
- Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the Baseline visit;
- In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with BSCT
21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
|
The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base. Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Time Frame: 8 weeks
|
Adverse events and any changes in physical examinations will be monitored, as described in the Code of Federal Regulations (CFR) Title 21 Part 312.
In particular local cutaneous irritation including erythema, peeling, dryness, itching, and burning/ stinging that first occur during the study or represent a worsening from Baseline will be recorded as AEs.
|
8 weeks
|
Pharmacokinetics - Measure Serum Concentration of Total Sheep IgG Using an ELISA.
Time Frame: 28 days
|
To determine PK, blood levels of sheep IgG were measured in samples collected at Visit 2 (Baseline), Visit 5, predose at Visit 6 (EOT), and then at 1 h, 2 h, and 4 h after the last dose of study medication.
|
28 days
|
Pharmacokinetics - Measure Subject Antibody Response to the Active Pharmaceutical Ingredient Using an Indirect Fluorescent Immuno Assay.
Time Frame: 8 weeks
|
The active ingredient of BSCT is sheep IgG which may causes an immunogenic response if it enters the systemic circulation.
To monitor this response patient blood samples collected at Screening, Visit 2 (Baseline), Visit 6 (EOT), and at Visit 8 (EOS) was tested for anti-sheep IgG antibodies (indicative of immune response against API).
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Angus Gidely-Baird, PhD, Scientific Director - Biosceptre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Protocol BSCT-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Basal Cell (BCC)
-
Pulse Biosciences, Inc.CompletedBCC | BCC - Basal Cell Carcinoma | Excision MarginUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
Carmel Medical CenterUnknownBasal Cell Carcinoma (BCC)Israel
-
Biofrontera Bioscience GmbHAccovion GmbHCompletedBasal Cell Carcinoma (BCC)Germany
-
University of AleppoAleppo University HospitalRecruitingBasal Cell Carcinoma | BCCSyrian Arab Republic
-
Oshadi Drug AdministrationCompleted
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Vejle HospitalNot yet recruitingSkin Diseases | Eyelid Diseases | Eyelid Tumor | BCC | BCC - Basal Cell Carcinoma
-
Stanford UniversityCompletedSkin Cancer | Basal Cell Carcinoma (BCC)United States
-
Bristol-Myers SquibbExelixisCompletedBasal Cell Carcinoma (BCC) | Hedgehog Pathway | Smoothened | Basal Cell Nevoid Syndrome (BCNS)United States, Canada
Clinical Trials on Treatment with BSCT
-
Universidad Complutense de MadridRecruitingMalocclusion, Angle Class II | DistalizationSpain
-
Helsinki University Central HospitalActive, not recruitingto Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm
-
University Hospital, LilleMinistry of Health, France; Laboratoire français de Fractionnement et de BiotechnologiesTerminatedHeart FailureFrance
-
Odense University HospitalNovo Nordisk A/S; Department of Nephrology, Odense University Hospital; The A... and other collaboratorsRecruitingKidney Failure, Chronic | Kidney Injury | Risk Reduction | Contrast-induced NephropathyDenmark
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly
-
The Metis FoundationUnited States Army Institute of Surgical ResearchCompletedHypertrophic ScarUnited States
-
Medical University of GrazRecruitingCarpal Tunnel SyndromeAustria
-
Wroclaw Medical UniversityCompletedCaries,Dental | Aerosol DiseasePoland
-
Mativa-Tech SARecruitingNASH - Nonalcoholic SteatohepatitisFrance
-
The Hospital for Sick ChildrenCompleted